BioSpace News Archive

The Lundquist Institute has announced the second in its new series of online webinars, “The Lundquist Community Science Series.” This community service webinar series features internationally-renowned Lundquist investigators and clinician scientists, who will be addressing timely topics on biomedical research and healthcare on a regular basis.

Novel, plasmid-free manufacturing system reduces cost of goods and improves AAV quality to enable development of safer gene therapies

Cognizant’s Expert Support of Medical Device Organizations and Digital Transformation Capabilities Cited in New PEAK Matrix Assessment

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today initiation of a program to construct and test a multivalent peptide vaccine for Alzheimer’s disease (AD). The critical first steps in vaccine development will be carried out by VIDO-Inte

Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ technology with release of the new RNA-Protein Co-Detection Assays. The RNAs

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it will host a virtual Key Opinion Leader (KOL) event on locally advanced pancreatic cancer on Friday, October 2, 2020, at 11 a.m. EDT. Sarah Hoffe, M.D., will provide a review of the manageme

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 75 patients, which is 50% of its enrollment target, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.

BioCanRx, Canada’s Immunotherapy Network, today announced funding of $10M for 14 cancer immunotherapy research projects and eight core and biomanufacturing facilities

Congenica, a digital health company enabling rapid and accurate analysis of complex genomic data, has launched a new module for its genomic analysis platform that will accelerate research into the relationship between an individual’s genomic variation and COVID-19 susceptibility, severity, and clinical outcomes.

Following recently unveiled plans by J. Small Investments, in partnership with Lyda Hill Philanthropies, for a 23-acre, mixed-use office campus designed to bolster local biotech, social impact and corporate innovation, Pegasus Park announces that BioLabs, headquartered in Cambridge, MA, has selected Dallas as its first location in the central United States.